Practice guidelines have recommended outpatient care for
hemodynamically - stable pulmonary embolism patients. But, what is currently
been administered is inpatient based.
The aim of the study was to assess the effectiveness of outpatient care
for PE patients and prove that it is not inferior to inpatient care.
In a recently
publicized study by Drahomir et al
an open-label, randomized non-inferiority trial was
conducted at 19 emergency departments in the USA, Switzerland, France and
Between February, 2007, and June, 2010, 344 eligible
patients with acute, symptomatic pulmonary embolism were enrolled in the study.
The patients were 18 years or older.
The researchers defined
pulmonary embolism as the acute onset of dyspnea or chest pain
along with a new contrast filling defect on computed tomography or pulmonary
angiography or a new high-probability ventilation-perfusion lung scan. It may
also be a documentation of a new proximal deep vein thrombosis either by venous
ultrasonography or contrast venography.
were randomly assigned to two
Initial outpatient treatment (patients were
discharged from hospital ≤24 h after randomization)
Inpatient treatment with
subcutaneous enoxaparin for approximately 5 days followed by oral
anticoagulation for about 90 days.
The researchers designed the Outpatient
Treatment of Pulmonary Embolism (OTPE) trial to compare and evaluate the safety
and efficiency of outpatient care versus inpatient care for low-risk patients
with acute, symptomatic pulmonary embolism against a validated clinical
The pulmonary embolism
severity index is a clinical prognostic model that was created and validated in
over 16 000 patients with pulmonary embolism.
with one or more of the following
characteristics were excluded:
Systolic blood pressure
of less than 100 mm Hg
Chest pain necessitating
Those with high risk of
bleeding (defined as stroke during the preceding 10 days, gastrointestinal
bleeding during the preceding 14 days or fewer than 75 000 platelets per
Severe renal failure (creatinine
clearance of <30 mL per min based on the Cockcroft-Gault equation),
Extreme obesity (body
mass >150 kg),
heparin-induced thrombocytopenia or allergy to heparins, therapeutic oral
anticoagulation at the time of diagnosis of pulmonary embolism
Any barriers to
treatment adherence or follow-up (eg, current alcohol abuse, illicit drug use,
psychosis, dementia, or homelessness),
Diagnosis of pulmonary
embolism more than 23 hrs before screening time (to avoid enrolling already
Previous enrolment in
In both treatment groups,
early initiation of oral anticoagulation with vitamin K antagonists such as
(warfarin, acenocoumarol, phenprocoumon, or fluidione) was recommended along
with its continuation for a minimum of 90 days.
All patients were contacted every day for the
week after enrolment and at 14, 30, 60, and 90 days and were asked about
symptoms of recurrent venous (VTE) such as dyspnoea, chest pain, leg pain,
swelling, bleeding, and any use of health-care resources.
All patients were instructed to report about any new symptoms suggestive of
Results & Discussion
- In selected low-risk patients with pulmonary
embolism, outpatient care can safely and effectively be used in place of
The study revealed that
outpatient treatment with low-molecular-weight heparin is not inferior to
inpatient treatment in terms of effectiveness and safety.
The study demonstrated
that out - patient care was well received by patients who were equally
satisfied with their care as were the inpatients.
Another beneficial factor
was that outpatient treatment also reduced hospital time.
"Outpatient versus inpatient treatment for patients with acute
pulmonary embolism: an international, open-label, randomised, non-inferiority
Drahomir et al
The Lancet, Volume
378, Issue 9785, Pages 41 - 48, 2 July 2011